|
|
 |
|
Viewing report
|
|
|
|
Prexige: Innovative Strategies To Ensure Commercial Gain
Datamonitor, Aug 2003, Pages: 35
Introduction
If blockbuster revenues are to be realized, Novartis needs to be innovative, especially as Prexige (lumiracoxib) is the sixth Cox-ii inhibitor brand to enter this stagnating market. Novartis is currently addressing the main issue of CV safety with the ongoing Target study, although other issues need to be considered to ensure optimum growth.
Scope
- Analysis of the global Cox-ii inhibitor market, with emphasis on key opportunities and barriers top growth
- Predicted outlook for Prexige through analysis of clinical trial data, company strategy, and competitive activity, while providing key recommendations
- Forecasts of Cox-ii inhibitor brand sales to 2011, with scenario forecasts to provide extra insight into potential market dynamics
Report Highlights
The success of Prexige will largely depend on its safety profile and the ability of Novartis to differentiate this product and promote it aggressively among physicians.
The results of the Target study will be key in positioning this product in the arthritis market, which is rapidly becoming saturated. However, on a platform of improved CV safety over rivals, Prexige will be able to gain a share of other key markets, such as acute and chronic pain.
Reasons to Purchase
- Understand why Novartis has implemented an enormous clinical development program, which will ultimately involve over 30,000 arthritis/ pain patients
- Define what is needed to differentiate a Cox-ii inhibitor and thus compete in a market dominated by pharmaceutical giants Merck and Pfizer
- Optimize product positioning by understanding strategies being employed by Novartis to ensure blockbuster revenues within the next eight years
Customers who bought this item also bought
Pain Therapeutics - Drugs, Markets and Companies
COX-2 Inhibitors - Biology, Therapeutic Agents & Markets
COX-2 withdrawal - Therapeutic, R&D and pharmaceutical impact
Pipeline Insight: Osteoarthritis - The Wait for a DMOAD Continues
Pain Management - Global Trends
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
Pain Therapeutics 2005:Market Dynamics and Outlook
The Future of eClinical Trial Solutions – Market Forecasts to 2015, Competitive Benchmarking and Case Studies
Pain Management - Global Strategic Business Report
The Global Pain Therapeutics Market: Market Analysis, R&D Pipelines and Competitive Landscape
Proteases as Drug Targets: Technologies and Opportunities for Drug Discovery
The Global Pain Therapeutics Market, 3rd Edition - Market Analysis, R&D Pipelines and Competitive Landscape
|
|
|
|
